【摘要】 目的研究头孢哌酮/舒巴坦治疗胆道感染的临床疗效和安全性。方法前瞻性、多中心研究159例确诊为胆道感染并接受头孢哌酮/舒巴坦治疗的住院患者,评价其临床疗效、细菌学疗效与不良反应。结果头孢哌酮/舒巴坦治疗胆道感染的临床有效率为86.78%;患者经治疗后发热迅速缓解,平均退热时间(3.09±1.81)d;头孢哌酮/舒巴坦治疗的细菌学清除率为85.71%;研究中无不良反应发生。结论头孢哌酮/舒巴坦可作为经验性治疗胆道感染的首选药物之一。更多还原

【Abstract】 OBJECTIVE To evaluate the safety and clinical efficacy of cefoperazone/sulbactam in the treatment of biliary tract infections.METHODS In this prospective multicenter study,159 hospitalized patients with biliary tract infections received cefoperazone/sulbactam,and the clinical and bacteriological efficacy as well as the side effects were evaluated.RESULTS The clinical effective rate of cefoperazone/sulbactam in the treatment of biliary tract infections was 86.78%.After treatment,the body temperature reduced to normal rapidly,the average time of defervescence was 3.09±1.81 days.Pathogen eradication rate was 85.71%.No adverse reactions were reported during the study period.CONCLUSIONS Cefoperazone/sulbactam can be used as one of antibiotics of choice in the initial empirical therapy for biliary tract infections.更多还原